MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.…
MaxCyte, Inc. Q3 2026 Earnings Call Summary
MaxCyte (NASDAQ: MXCT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 91 employees.
The shares were at 1.370 USD on 20 November 2026, down 4.9% over 52 weeks. Its 52-week range is 0.6430 USD to 1.805 USD: the price is 24.1% below the high and 113.1% above the low.
Its market capitalisation is 141.45M USD.
MaxCyte reports return on equity of -26.0%, an operating margin of -85.5% and revenue up 48.7% year over year.
It holds more cash than debt, a net cash position of 84.39M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 4.107 USD is 199.8% above the current price. The next earnings report is expected on 23 March 2027.